Solventum Launches $1B Buyback After $2B Q4 Revenue and Acera Acquisition
Solventum posted Q4 revenue of $2.0B, up 3.5% organically but down 3.7% after the Purification & Filtration sale and Acera Surgical acquisition, with non-GAAP EPS of $1.57. Management initiated a $1B share repurchase, entered the synthetic tissue market via Acera, and guided 2%–3% organic growth and $6.40–$6.60 EPS for 2026.
1. Q4 Financial Performance
Solventum reported fourth-quarter revenue of $2.0 billion, reflecting 3.5% organic growth offset by a 3.7% reported decline following the Purification & Filtration divestiture and Acera Surgical acquisition. Gross margin came in at 53.5%, and the company delivered non-GAAP EPS of $1.57, driven primarily by volume gains in MedSurg and Dental segments.
2. Portfolio Moves and Capital Allocation
During the quarter Solventum sold its Purification & Filtration unit, closed the Acera Surgical acquisition to access the synthetic tissue market, and launched a $1 billion share repurchase plan aimed at offsetting stock-based compensation dilution. Management retains flexibility to expand repurchases based on performance and board approval.
3. 2026 Outlook and Strategic Initiatives
For fiscal 2026 Solventum guides 2%–3% organic sales growth, a 21%–21.5% operating margin, and $6.40–$6.60 EPS, supported by five core growth drivers and continued SKU rationalization. The company expects to exit roughly 90% of 3M transition service agreements by year-end and manage tariff exposures of about $100–$120 million.